Mitotech, SA   Report issue

For profit Phase 3
Founded: Luxembourg (2009)

Organization Overview

First Clinical Trial
2014
NCT02121301
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mitotech, SA

Active Ingredients

Drugs in Phase 3 Trials (1)

Visomitin (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Keratoconjunctivitis (Phase 2)

Keratoconjunctivitis Sicca (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1